SSRI / SNRI treatment-record nexus evidence
How antidepressant prescriptions strengthen your MDD claim (and unlock more).
The SSRI and SNRI prescription history in your VA pharmacy records is more than a list of refills — it is a documented longitudinal record of MDD severity, chronicity, and treatment response. Three patterns matter for claims:
1. SSRI / SNRI prescriptions chronicle the severity of your MDD. Common antidepressants prescribed for veterans with MDD include citalopram (Celexa), sertraline (Zoloft), fluoxetine (Prozac), escitalopram (Lexapro), paroxetine (Paxil), venlafaxine (Effexor), duloxetine (Cymbalta), and bupropion (Wellbutrin). When the VA pharmacy record shows continuous prescriptions over months or years — multiple refills, dose escalations, augmentation with atypical antipsychotics, or switches between agents — that record constitutes chronic-disease documentation that the rater cannot dismiss. The pharmacy record proves: (1) the condition is real and requires maintenance medication, not transient distress; (2) the VA has been treating it as a diagnosed condition over time; (3) the veteran has been compliant with treatment, which strengthens the credibility of the symptom picture. Pull your VA pharmacy record through MyHealtheVet and include it with your claim — fill dates, dosage changes, and duration of each agent are all visible.
2. The SSRI / SNRI class is itself a nexus source for additional secondary claims. Long-term SSRI and SNRI use produces a number of well-documented secondary conditions that can each be filed independently: erectile dysfunction (serotonin-mediated suppression of libido and arousal — the most common and most compensable; file for Special Monthly Compensation under SMC-K), bruxism (SSRI-induced jaw-clenching and tooth-grinding, ratable as a dental / TMJ condition), gastrointestinal symptoms (nausea, IBS-pattern complaints, altered gut motility — serotonin's role in gut function), and weight changes (significant weight gain or loss documented over the prescription period). Each one of these is a separate nexus letter opportunity and a separate secondary claim. The medication list that supports your MDD claim also supports each downstream condition — make sure your treating provider documents each side-effect as it appears.
3. Treatment-resistance is one of the strongest severity signals the VA has. Treatment-resistant depression — failed first-line SSRI, dose escalation without adequate response, augmentation with an atypical antipsychotic (aripiprazole, quetiapine), switch to an SNRI, switch to bupropion, trial of an MAOI or ketamine — is direct clinical evidence that you are at the more severe end of the MDD spectrum. The 38 CFR 4.130 rating ladder treats "reduced reliability and productivity" (50%) and "deficiencies in most areas" (70%) as the next steps up from "moderate" impairment, and the most clinically defensible way to demonstrate that the veteran has crossed those thresholds is to show that standard first-line treatment did not work. A treatment record that shows two failed SSRIs followed by an SNRI trial and an atypical augmentation directly supports a 50%–70% rating — far stronger than the symptom-gradient evidence usually available.
38 CFR 4.130 — How SSRIs-as-treatment evidence fits the regulation's overall-impairment language
The General Rating Formula for Mental Disorders is anchored in the language "the rating agency shall consider the level, frequency, severity, and duration of symptoms" along with "the length of time and percentage of incapacitation" required to produce the impairment picture. SSRI / SNRI pharmacy records hit every element of that test.
Frequency: daily refill cadence over years shows the disorder is not episodic. Duration: continuous prescription coverage measures chronicity in months and years. Severity: dose escalation, augmentation, and switches to higher-potency agents are direct clinical markers that first-line treatment was insufficient. Length of incapacitation: treatment-resistance extends the period of partial or total occupational and social dysfunction past the point where any reasonable clinician would expect remission. Together, these data points anchor an MDD rating at 50%–70% even when the veteran's current symptom picture, on a good day, would otherwise look like 30%.